1.Research advances in chest tightness variant asthma.
Jia Ling CHEN ; Li SHA ; Chuan He LIU
Chinese Journal of Preventive Medicine 2023;57(3):327-332
Chest tightness variant asthma (CTVA) is a special type of asthma with chest tightness as the only or main symptom. Due to the lack of typical asthma symptoms such as coughing, wheezing, shortness of breath, and positive signs in chest, it is easy to be missed or misdiagnosed in clinical practice. The onset of chest tightness variant asthma is insidious, and there is few research and attention both domestic and international, so there is no unified diagnosis and treatment standard especially in childhood asthma. This article expounds the related research advances in chest tightness variant asthma, in order to increase clinical attention and provide reference and basis for the prevention of the disease as well as the formulation of diagnosis and treatment strategies.
Humans
;
Asthma/drug therapy*
;
Cough
;
Surveys and Questionnaires
;
Records
2.Effect of Jiuwei Zhuhuang Powder on Cough Resolution in Children with Upper Respiratory Tract Infections: A Multicenter Randomized Controlled Trial.
Hui LUO ; Gui-Hua SONG ; Xiao-Jian MA ; Meng-Meng SUN ; Man ZHANG ; Jian-Rong XIE ; Shao PENG
Chinese journal of integrative medicine 2022;28(5):387-393
OBJECTIVE:
To assess the effectiveness of Jiuwei Zhuhuang Powder (JWZH), a Tibetan patent medicine in treating upper respiratory tract infection (URTI) associated cough in children.
METHODS:
The study was a multicenter, randomized, open-label, controlled trial. A total of 142 children aged 2 to 14 years old, with URTI-associated cough within 48 h of onset, were randomly assigned to two groups at a 1:1 ratio by computer-generated randomization sequence. Children were treated with JWZH (1 to 1.5 g, twice to thrice daily) in the treatment group or conventional treatment (Pediatric Paracetamol, Artificial Cow-bezoar and Chlorphenamine Maleate Granules, 0.25 to 1 g, thrice daily) in the control group for 5 days. The primary endpoints were the time to cough resolution and 4-day cough resolution rate. The secondary endpoints were the daily improvement in symptom scores and cough resolution rate during the study period.
RESULTS:
A total of 138 children were included in the intention-to-treat analysis, with 71 cases in the treatment group and 67 cases in the control group. Compared with the conventional treatment, the children receiving JWZH had a shorter time to cough resolution [hazard ratio, 2.10; 95% confidence interval (CI), 1.29-3.40; P=0.003]. The median time to cough resolution for children receiving JWZH was shorter than that of the conventional treatment (2 days vs. 3 days; P<0.001). The 4-day cough resolution rate in the JWZH group was higher than that of the control group (94.4% vs. 74.6%; risk difference: 19.8%, 95% CI: 8.1%-31.5%; relative risk: 1.265, 95% CI: 1.088-1.470; P=0.001). There were no statistically significant differences in the improvement of other symptoms caused by URTI (P>0.05). Adverse events was reported in 5.6% (4/71) and 4.5% (3/67) in participants of JWZH and PPACCM groups (P>0.05), respectively, which were all mild and resolved without treatment.
CONCLUSION
JWZH seemed to be a safe and effective therapy for URTI-associated cough in children. (Trial registration No. ChiCTR2000039421).
Child
;
Cough/drug therapy*
;
Drugs, Chinese Herbal
;
Humans
;
Nonprescription Drugs
;
Powders
;
Respiratory Tract Infections/drug therapy*
3.Research progress of Shegan Mahuang Decoction and predictive analysis on its Q-markers.
Qiu-Hui LI ; Xiao-Xiao SHAN ; Wei-Dong YE ; Xun-Yan YIN ; Ya-Mei YUAN ; Xiang-Ming FANG
China Journal of Chinese Materia Medica 2023;48(8):2068-2076
Shegan Mahuang Decoction has been used in clinical practice for thousands of years, and is a classical formula for treating asthma and other respiratory diseases, with the effects of ventilating lung, dispersing cold, and relieving cough and asthma. This paper summarized the history, clinical application and mechanism of Shegan Mahuang Decoction, and predicted its quality markers(Q-markers) based on the "five principles" of Q-markers. The results suggested that irisflorentin, tectoridin, tectorigenin, irigenin, ephedrine, pseudoephedrine, asarinin, methyleugenol, shionone, epifriedelanol, tussilagone, 6-gingerol, trigonelline, cavidine, schizandrin, and schizandrin B could be used as Q-markers of Shegan Mahuang Decoction, which provided a basis for the quality control and subsequent research and development of Shegan Mahuang Decoction.
Humans
;
Ephedra sinica
;
Drugs, Chinese Herbal/pharmacology*
;
Asthma/drug therapy*
;
Lung
;
Cough/drug therapy*
4.Efficacy of intramuscular injection of Xiyanping injection for the treatment of acute bronchitis in children: a multicenter, randomized, parallel-controlled clinical study.
Qiang CHEN ; Xiao-Hua ZHU ; Yang LIU ; Lan LI ; Jing-Hua LUO ; Yan-Yan ZHANG ; Juan HUANG ; Xiao-Chun CAO ; Xiao-Hua SONG ; Fang-Rui WAN
Chinese Journal of Contemporary Pediatrics 2023;25(11):1107-1112
OBJECTIVES:
To study the efficacy and safety of Xiyanping injection through intramuscular injection for the treatment of acute bronchitis in children.
METHODS:
A prospective study was conducted from December 2021 to October 2022, including 78 children with acute bronchitis from three hospitals using a multicenter, randomized, parallel-controlled design. The participants were divided into a test group (conventional treatment plus Xiyanping injection; n=36) and a control group (conventional treatment alone; n=37) in a 1:1 ratio. Xiyanping injection was administered at a dose of 0.3 mL/(kg·d) (total daily dose ≤8 mL), twice daily via intramuscular injection, with a treatment duration of ≤4 days and a follow-up period of 7 days. The treatment efficacy and safety were compared between the two groups.
RESULTS:
The total effective rate on the 3rd day after treatment in the test group was significantly higher than that in the control group (P<0.05), while there was no significant difference in the total effective rate on the 5th day between the two groups (P>0.05). The rates of fever relief, cough relief, and lung rale relief in the test group on the 3rd day after treatment were higher than those in the control group (P<0.05). The cough relief rate on the 5th day after treatment in the test group was higher than that in the control group (P<0.05), while there was no significant difference in the fever relief rate and lung rale relief rate between the two groups (P>0.05). The cough relief time, daily cough relief time, and nocturnal cough relief time in the test group were significantly shorter than those in the control group (P<0.05), while there were no significant differences in the fever duration and lung rale relief time between the two groups (P>0.05). There was no significant difference in the incidence of adverse events between the two groups (P>0.05).
CONCLUSIONS
The overall efficacy of combined routine treatment with intramuscular injection of Xiyanping injection in the treatment of acute bronchitis in children is superior to that of routine treatment alone, without an increase in the incidence of adverse reactions.
Humans
;
Child
;
Injections, Intramuscular
;
Cough/drug therapy*
;
Prospective Studies
;
Respiratory Sounds
;
Bronchitis/drug therapy*
;
Treatment Outcome
5.Efficacy and Safety of Lianhua Qingwen for Patients with COVID-19: A Systematic Review and Meta-Analysis.
Xiao-Hu SUN ; Shuo ZHANG ; Zhen YANG ; Zhen-Lin CHEN ; Shi-Jun YUE ; Sai ZHANG ; Yu-Ping TANG
Chinese journal of integrative medicine 2022;28(7):650-660
BACKGROUND:
Corona virus disease 2019 (COVID-19) has spread around the world since its outbreak, and there is no ascertained effective drug up to now. Lianhua Qingwen (LHQW) has been widely used in China and overseas Chinese, which had some advantages in the treatment of COVID-19.
OBJECTIVE:
To evaluate the efficacy and safety of LHQW for COVID-19 by conducting a systematic review with meta-analysis.
METHODS:
A comprehensive literature search was conducted in 12 electronic databases from their establishment to October 30, 2021. Note Express 3.2.0 was used for screening of trials, and the data was independently extracted in duplicate by 2 researchers. The risk of bias of randomized controlled trials (RCTs) and retrospective studies were assessed by using the Cochrane collaboration tool and Newcastle Ottawa Scale, respectively, followed by data analysis using RevMan 5.3. The RCTs or retrospective studies to treat COVID-19 using LHQW were included. The intervention measures in the experimental group were LHQW alone or combined with chemical drugs (LCWC), and that in the control group were chemical drugs (CDs). Outcome measures included computed tomography (CT) recovery rate, disappearance rates of primary (fever, cough, fatigue), respiratory, gastrointestinal and other symptoms, exacerbation rate and adverse reaction. Subgroup analysis was conducted according to whether LHQW was combined with CDs and the different treatment methods in the control group.
RESULTS:
Nine trials with 1,152 participants with COVID-19 were included. The CT recovery rates of LHQW and LCWC were 1.36 and 1.32 times of CDs, respectively (P<0.05). Compared with CDs, LCWC remarkably increased the disappearance rates of fever, cough, fatigue, expectoration, shortness of breath, and muscle soreness (P<0.05). LHQW also obviously decreased the exacerbation rate, which was 0.45 times of CDs alone (P<0.05). There was no obvious difference between LCWC and CDs in adverse reaction (P>0.05).
CONCLUSIONS
LHQW was more suitable for treating COVID-19 patients with obvious expectoration, shortness of breath and muscle soreness. LHQW had advantages in treating COVID-19 with no obvious exacerbation. (PROSPERO No. CRD42021235937).
COVID-19/drug therapy*
;
Cough/drug therapy*
;
Drugs, Chinese Herbal/adverse effects*
;
Dyspnea/drug therapy*
;
Fatigue/drug therapy*
;
Humans
;
Myalgia/drug therapy*
6.Wheeze in childhood: is the spacer good enough?
Veena RAJKUMAR ; Barathi RAJENDRA ; Choon How HOW ; Seng Bin ANG
Singapore medical journal 2014;55(11):558-discussion 563
Max was treated with SABA using an MDI and spacer with facemask and responded well to the initial treatment. You explained to the parents that nebulisers are neither required nor recommended in the treatment of wheezing in their child's situation. You advised the parents on the proper technique of MDI use with spacer and facemask, as well as care of the equipment. You also gave them a clearly written action plan regarding the efficient management of the next episode of wheeze with MDI and spacer. You further explained the side effects of oral bronchodilators and nebulisers, and why you refrained from using them. Max was given a follow-up appointment to assess his progress, and his parents were advised on the situations when they should go to a doctor or the emergency department.
Asthma
;
drug therapy
;
Child
;
Cough
;
Drug Delivery Systems
;
Humans
;
Inhalation Spacers
;
Nebulizers and Vaporizers
;
Respiratory Sounds
7.Analysis on principle of treatment of cough of yan zhenghua based on apriori and clustering algorithm.
Jia-Rui WU ; Wei-Xian GUO ; Xiao-Meng ZHANG ; Bing YANG ; Bing ZHANG
China Journal of Chinese Materia Medica 2014;39(4):623-626
Based on the data mining methods of association rules and clustering algorithm, the 188 prescriptions for cough that built by Yan Zhenghua were collected and analyzed to get the frequency of drug usage and the relationship between drugs. From which we could conclude the experiences of Yan Zhenghua for the treatment of cough. The results of the analysis were that 20 core combinations were dig out, such as Bambusae Caulis in Taenias-Almond-Sactmarsh Aster. And there were 10 new prescriptions were found out, such as Sactmarsh Aster-Scutellariae Radix-Album Viscum-Bambusae Caulis in Taenian-Eriobotryae Folium. The results of the analysis were proved that Yan Zhenghua was good at curing cough by using the traditional Chinese medicine that can dispel wind and heat from the body, and remove heat from the lung to relieve cough.
Algorithms
;
Cough
;
drug therapy
;
Data Mining
;
Drug Prescriptions
;
Drug Therapy, Combination
;
Drugs, Chinese Herbal
;
therapeutic use
;
Humans
;
Practice Patterns, Physicians'
8.Clinical effect of fluticasone propionate, montelukast sodium and ketotifen in treatment of cough variant asthma in children.
Xiao-Hong ZHU ; Jin-Wei TU ; Ji-Hong DAI
Chinese Journal of Contemporary Pediatrics 2019;21(4):393-398
OBJECTIVE:
To study the clinical effect of different combinations of fluticasone propionate (Flu), montelukast sodium (Mon) and ketotifen (Ket) in the treatment of children with cough variant asthma (CVA).
METHODS:
A total of 280 children with CVA who were admitted to the department of respiratory medicine from June 2015 to January 2018 were randomly divided into Flu+Mon+Ket, Flu+Mon, Flu+Ket, Mon+Ket, Flu, Mon and Ket groups, with 40 children in each group. The children in each group were given corresponding drug(s), and the course of treatment was 3 months for all groups. The condition of cough, cough symptom score, pulmonary function and adverse drug reactions were evaluated after 2 and 3 months of treatment. The children were followed up to observe recurrence.
RESULTS:
After treatment, cough symptom score tended to decrease in all 7 groups, with increases in percentage of forced expiratory volume in 1 second (FEV1%) and percentage of predicted peak expiratory flow (PEF%). After 2 months of treatment, the Flu+Mon+Ket group had a significantly lower cough symptom score and significantly higher FEV1% and PEF% than the other groups (P<0.05). After 2 and 3 months of treatment, the Ket group had a significantly higher cough symptom score and significantly lower FEV1% and PEF% than the other groups (P<0.05). After 3 months of treatment, there were no significant differences in cough symptom score, FEV1% and PEF% among the other groups (P>0.05). There was a low incidence rate of adverse events in all 7 groups, and there was no significant difference among the 7 groups (P>0.05). The Ket group had a significantly higher recurrence rate of cough than the other groups (P<0.001), while there was no significant difference in this rate among the other groups (P>0.0024).
CONCLUSIONS
For children with CVA, a combination of Flu, Mon and Ket has a better clinical effect than a combination of two drugs and a single drug at 2 months of treatment and is safe. After 3 months of treatment, Flu or Mon alone has a similar effect to drug combination. Ket alone has a poor clinical effect and a high recurrence rate after drug withdrawal.
Acetates
;
Androstadienes
;
Anti-Asthmatic Agents
;
Asthma
;
drug therapy
;
Child
;
Cough
;
drug therapy
;
Drug Combinations
;
Fluticasone
;
Humans
;
Ketotifen
;
Quinolines
9.Systematic review and Meta-analysis of Lianhua Qingwen preparations combined with Oseltamivir in treatment of influenza.
Yu-Meng YAN ; Xiao-Jing YANG ; Chun-Xia ZHAO ; Ze-Yu LI ; Guo-Zhen ZHAO ; Yu-Hong GUO ; Bo LI ; Qing-Quan LIU
China Journal of Chinese Materia Medica 2022;47(15):4238-4247
This study aims to explore the efficacy and safety of Lianhua Qingwen preparations combined with Oseltamivir in the treatment of influenza patients. PubMed, Cochrane Library, EMbase, SinoMed, CNKI, Wanfang, and VIP were searched for the randomized controlled trials(RCTs) involving the comparison between the influenza patients treated with Lianhua Qingwen preparations combined with Oseltamivir and those treated with Oseltamivir alone. Fever clearance time was taken as the primary outcome indicator. Clinical effective rate(markedly effective and effective), time to muscle pain relief, time to sore throat relief, time to cough relief, time to nasal congestion and runny nose relief, time to negative result of viral nucleic acid test, and adverse reactions were taken as the secondary outcome indicators. The data were extracted based on the outcome indicators and then combined. The Cochrane collaboration's tool for assessing risk of bias was used to evaluate the quality of a single RCT, and the grading of recommendations assessment, development and evaluations(GRADE) system to assess the quality of a single outcome indicator. RevMan 5.3 was employed to analyze data and test heterogeneity. Finally, 16 RCTs involving 1 629 patients were included for analysis. The Meta-analysis showed that Lianhua Qingwen preparations combined with Oseltamivir was superior to Oseltamivir alone in the treatment of influenza in terms of clinical effective rate(RR=1.16, 95%CI [1.12, 1.20], P<0.000 01), fever clearance time(SMD=-2.02, 95%CI [-2.62,-1.41], P<0.000 01), time to muscle pain relief(SMD=-2.50, 95%CI [-3.84,-1.16], P=0.000 2), time to sore throat relief(SMD=-1.40, 95%CI [-1.93,-0.85], P<0.000 01), time to cough relief(SMD=-1.81, 95%CI [-2.44,-1.19], P<0.000 01), time to nasal congestion and runny nose(SMD=-2.31, 95%CI [-3.61,-1.01], P=0.000 5), and time to negative result of viral nucleic acid test(SMD=-0.68, 95%CI [-1.19,-0.16], P=0.01). However, due to the low quality of the trials, the above conclusions need to be proved by more high-quality clinical studies. In addition, we still need to attach importance to the adverse reactions of the integrated application of Chinese and western medicines.
Cough/drug therapy*
;
Drugs, Chinese Herbal/adverse effects*
;
Humans
;
Influenza, Human/drug therapy*
;
Myalgia/drug therapy*
;
Nucleic Acids/therapeutic use*
;
Oseltamivir/adverse effects*
;
Pharyngitis/drug therapy*
;
Rhinorrhea
10.Chronic Cough and Sinusitis in Children: The Role of Antimicrobials.
Duk Jin YUN ; Chang Ho HONG ; Ki Keun OH
Yonsei Medical Journal 1983;24(1):67-75
We evaluated the role of antimicrobials in the treatment of chronic maxillary sinusitis in children with chronic cough. At the first visit 216 of 276 cases with chronic cough had radiologically abnormal maxillary sinuses (78.3%). By the Waters x-rays around 50 cases each were assigned randomly to four groups; among them, 48 cases were given an amoxicillin, 51 cases were given trimethoprim-sulfamethoxazole (TMS), 53 cases were given amoxcillin plus TMS and 50 cases were given expectorant plus decongestant (control) group. Thus, 202 children were included for data analysis. Treatment was given for two weeks in each group. The group treated with antimicrobials had a significantly higher cure rate than that of expectorant plus decongestant group (P < 0.001). Most of the patients who had roentgenographic improvement have successfully recovered from the chronic cough and the other cardinal signs of chronic sinusitis.
Adolescent
;
Anti-Infective Agents/therapeutic use*
;
Child
;
Child, Preschool
;
Chronic Disease
;
Cough/drug therapy*
;
Female
;
Human
;
Male
;
Sinusitis/drug therapy*